Verismo Reports Encouraging First-in-Human Data for SynKIR-110 in Solid Tumors

New updates have been reported about Verismo Therapeutics.

Verismo Therapeutics has reported its first human data for SynKIR-110, the lead asset from its proprietary multi-chain KIR-CAR platform, from the ongoing Phase 1 STAR-101 trial in advanced mesothelin-positive solid tumors. Initial results from nine patients across the first three dose-escalation cohorts show a favorable safety profile with no dose-limiting toxicities, no grade 3 or higher cytokine release syndrome, and no observed ICANS.

Data presented at the AACR 2026 Clinical Trial Plenary in San Diego indicate dose-dependent biologic and anti-tumor activity, including KIR-CAR T cell expansion, persistence, and serum cytokine changes. At the highest tested dose level to date, one of three patients achieved an ongoing partial response beyond three months at the September 2025 interim cutoff, supporting continued dose escalation to establish a recommended Phase 2 dose.

For Verismo, these outcomes are a key technical and strategic milestone that validate its core thesis that a split-signaling KIR-CAR architecture can sustain T cell function in hostile solid tumor microenvironments where conventional single-chain CAR T therapies often fail. The company’s platform, which separates antigen recognition from T cell activation using a modified NK cell-derived receptor and DAP12, is intended to reduce chronic signaling and T cell exhaustion, potentially enabling more durable responses.

STAR-101, a first-in-human, multicenter U.S. study in ovarian cancer, mesothelioma, and cholangiocarcinoma, is continuing enrollment with a planned expansion cohort once the Phase 2 dose is defined. Verismo, a subsidiary of HLB Innovation, now has two KIR-CAR candidates in Phase 1 trials, positioning the company to build a differentiated portfolio in both solid tumors and B cell malignancies if safety and efficacy are confirmed, with future value creation tied to trial progression, regulatory feedback, and partnering or financing options.